Compare QMCO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | EDSA |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 12.8M |
| IPO Year | N/A | N/A |
| Metric | QMCO | EDSA |
|---|---|---|
| Price | $7.09 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.50 | $13.00 |
| AVG Volume (30 Days) | ★ 461.7K | 34.5K |
| Earning Date | 02-11-2026 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,949,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $1.28 |
| 52 Week High | $90.64 | $4.49 |
| Indicator | QMCO | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 34.62 |
| Support Level | $7.07 | $1.27 |
| Resistance Level | $7.88 | $1.50 |
| Average True Range (ATR) | 0.66 | 0.09 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 2.29 | 23.64 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.